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Abstract
Purpose Prolonged postoperative ileus (POI) is a common complication after open abdominal surgery (OAS). Daikenchuto 
(DKT), a traditional Japanese medicine that peripherally stimulates the neurogenic pathway, is used to treat prolonged POI in 
Japan. To analyze whether DKT accelerates the recovery from prolonged POI after OAS, we conducted a secondary analysis 
of three multicenter randomized controlled trials (RCTs).
Methods A secondary analysis of the three RCTs supported by the Japanese Foundation for Multidisciplinary Treatment 
of Cancer (project numbers 39-0902, 40-1001, 42-1002) assessing the effect of DKT on prolonged POI in patients who had 
undergone OAS for colon, liver, or gastric cancer was performed. The subgroup included 410 patients with no bowel move-
ment (BM) before the first diet, a DKT group (n = 214), and a placebo group (n = 196). Patients received either 5 g DKT or 
a placebo orally, three times a day. The primary endpoint was defined as the time from the end of surgery to the first bowel 
movement (FBM). A sensitivity analysis was also performed on the age, body mass index and dosage as subgroup analyses.
Results The primary endpoint was significantly accelerated in the DKT group compared with the placebo group (p = 0.004; 
hazard ratio 1.337). The median time to the FBM was 113.8 h in the placebo group and 99.1 h in the DKT treatment group.
Conclusions The subgroup analysis showed that DKT significantly accelerated the recovery from prolonged POI following 
OAS.
Trial registration number UMIN000026292.
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Abbreviations
POI  Postoperative ileus
OAS  Open abdominal surgery
DKT  Daikenchuto
RCT  Randomized controlled trial
JFMC  The Japanese Foundation for Multidisciplinary 
Treatment of Cancer
BMI  Body mass index
HR  Hazard ratio
CI  Confidence interval
BM  Bowel movement
FBM  First bowel movement
Introduction
Postoperative ileus (POI), which is a routine and unavoid-
able consequence of major open abdominal surgery (OAS), 
is characterized by transient impairment of bowel motility 
[1–3]. Patients suffering from POI in the small and large 
intestines commonly recover 24–48 and 48–72 h after sur-
gery, respectively [3, 4]. Therefore, uncomplicated “normal” 
POI that resolves spontaneously within 2–3 days after sur-
gery is considered to be a physiological event [3, 4]. By 
contrast, prolonged POI, which continues postoperatively 
beyond day 4, is termed “pathologic POI” [1, 5]. Several 
mechanisms have been proposed to explain the pathogenesis 
of prolonged POI, especially that after OAS, including a dis-
turbance of the neurogenic pathway [5, 6]. Although several 
advances have been made in medical therapy to help reduce 
the incidence and severity of POI [5, 6], the number of peo-
ple suffering with this condition nonetheless remains high.
Daikenchuto (DKT), which is a mixture of extract pow-
ders from dried Japanese pepper, processed ginger and gin-
seng radix, is a scientifically validated and frequently pre-
scribed traditional Japanese Kampo medicine [7, 8]. Kampo 
medicines meet the strict specifications for coverage under 
the Japanese National Health Insurance plan, which is com-
parable to Western counterparts in terms of ensuring the 
quality and therapeutic efficacy. Furthermore, DKT, which is 
known to stimulate the enteric and sensory neural pathways 
in the intestinal wall, has been approved as an investiga-
tional drug by the US Food and Drug Administration. DKT 
is primarily used for the treatment of POI [7–9]. To gather 
clinical evidence, three randomized controlled trials (RCTs) 
supported by the Japanese Foundation for Multidisciplinary 
Treatment of Cancer (JFMC; project numbers 39-0902, 
40-1001, 42-1002) were conducted to determine whether 
or not DKT ameliorated POI [10–12]. The results of one of 
the RCTs indicated a significant decrease in time until the 
first passage of stool [11]. The remaining two RCTs showed 
a slight tendency toward amelioration of POI [10, 12].
Although there is a lack of consensus regarding the “nor-
mal” interval for distinguishing pathologic POI from physi-
ologic POI, a proposal and validation demonstrated the best 
endpoint to define pathologic POI to be the combination of 
the passage of stool and tolerance of solid food [1, 13].
Defecation [passing a bowel movement (BM)] is the ulti-
mate indicator of the intestinal motility. More than half of 
patients were reported to spontaneously recover from POI 
within three to four days (physiologic POI) after major lapa-
rotomy surgery, as determined by the resumption of BM [1, 
13]. These patients had already recovered from physiologic 
POI, and since the incidence of pathologic POI is low, it 
was believed that recurrent POI would be unlikely to occur 
again. We therefore hypothesize that the effect of DKT on 
“pathologic POI” might differ after excluding such low-risk 
patients.
In the present study, we investigated the effect of DKT on 
POI in patients with no BM before the first diet after OAS. 
Three RCTs were conducted without DKT pharmacokinetic 
data. A recent study showed that the concentrations of active 
DKT ingredients that enter the plasma may be lower in older 
patients than in younger ones and in those with a high body 
mass index (BMI) than in those with a low BMI [14]. The 
practical dosage of DKT is also a direct factor affecting the 
concentrations of active DKT ingredients. Thus, subpopula-
tions extracted by several conditions based on the values of 
these variables were used. Additional subpopulations used 
in the sensitivity analyses included patients with no remark-




This study was conducted in accordance with the tenets of 
the Declaration of Helsinki and was approved by the internal 
review boards of all participating institutions. This pooled 
analysis study was approved by the institutional review 
board of the JFMC.
Clinical trials and subgroup assignment
The three clinical trials (JFMC project numbers 39-0902, 
40-1001, and 42-1002) were performed to evaluate the clini-
cal benefits of DKT in POI after major OAS for cancer of 
the colon, liver, or stomach. These studies were planned by 
the study group “DKT Forum” consisting of surgeons in the 
different fields from 33 academic medical centers (22% of 
all academic medical centers in Japan), and the protocols 
were standardized as much as possible to enable pooled/
integrated post-analyses.
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A total of 862 enrolled patients were randomized to 
receive either 5 g DKT or placebo orally, three times a day, 
for a maximum of 12 days. The patients were observed 
for up to 14 days after surgery. Of these 862 patients, 122 
were excluded for the following reasons [JFMC39 (colon); 
50 excluded] 32 patients were considered ineligible for the 
study (8 had stoma; 7 had stage IV cancer; 5 had a his-
tory of laparotomy; 4 had complications, including ileus or 
hepatic disease; 3 were not diagnosed with colon cancer; 1 
underwent laparoscopic surgery; 1 declined to give informed 
consent; 1 had double cancer; and 2 were dismissed for other 
reasons), and 18 patients were not treated (7 could not be 
treated because of their circumstances, 5 suffered compli-
cations, 2 were intolerant to drug administration, 2 refused 
drug administration, 1 declined treatment after initiation 
of the study, and 1 could not receive treatment because of 
his conditions); [JFMC40 (liver); 22 excluded] 15 patients 
were considered ineligible for the study (4 in the DKT group 
and 11 in the placebo group; specifically, 7 did not receive 
surgery, 2 were unresectable cases, and 6 received chem-
otherapy within 6 weeks), and 7 in the DKT group were 
untreated (2 withdrew their consent, 1 rejected the treat-
ment, 2 were non-cancer patients, and 2 had their date of 
operation changed); [JFMC42 (stomach); 50 excluded] 38 
patients were considered ineligible for the study (19 in the 
DKT group and 19 in the placebo group; specifically, 22 did 
not undergo open total gastrectomy, 1 did not have surgery, 
3 had a history of laparotomy, 7 had another intestinal resec-
tion at the time of gastrectomy, 1 received chemotherapy in 
the preceding 4 weeks, and 4 withdrew their consent), and 
12 were not treated (1 each declined treatment, had anasto-
motic leakage, showed difficulty with oral intake, and had a 
liver functional disorder; 7 were not treated by the doctor’s 
recommendation, and 1 started DKT at postoperative day 3).
Among all patients enrolled and randomized in the 3 
RCTs, 740 patients who were eligible were ultimately 
included in the efficacy analysis.
Efficacy assessment
Efficacy analyses were based on the subgroup population as 
the main analysis set. Some of the efficacy endpoints for the 
subgroup analysis were the same as those used in the indi-
vidual RCTs. The primary endpoint of the current study was 
defined as the time from the end of surgery, defined as tra-
cheal tube extubation, to their first bowel movement (FBM). 
The same definition was used in the previous three studies. 
In addition, a sensitivity analysis was performed to evalu-
ate the reliability of the main result. The approach for the 
sensitivity analysis was identical to that used in the whole 
subgroup population, which was performed in subpopu-
lations according to several clinical features, such as age, 
BMI, dosage, history, present illness, and surgery-related 
complications (i.e., anastomotic leakage). The results 
were compared with those of the subgroup population and 
reported for both the primary outcome and the sensitivity 
analyses.
Statistical analyses
The primary endpoint was analyzed using survival analysis 
methods, including the Kaplan–Meier estimation, the log-
rank test, and a Cox regression analysis. The log-rank test 
and Cox regression analyses were performed with stratifica-
tion according to the organs that underwent surgery. When 
the time from tracheal tube extubation to the FBM could not 
be obtained due to withdrawal of participation in the clinical 
trial (n = 11), we excluded these subjects from the log-rank 
test and Cox regression analyses. To evaluate imbalances 
in background factors, the Cochran–Mantel–Haenszel test 
was used, again with consideration of differences accord-
ing to the organ undergoing surgery. A p value < 0.05 was 
considered statistically significant. All statistical analyses 
were performed using SAS version 9.3 (SAS Institute, Cary, 
NC, USA).
Results
Data from the 740 eligible patients, including 45.4%, 28.2% 
and 26.4% with colon, liver and gastric cancer, respectively, 
were pooled for the efficacy analysis sets. The subgroup pop-
ulation included 410 patients (DKT group, n = 214; placebo 
group, n = 196) who did not have a BM before the first diet 
after surgery [colon cancer, n = 152 (37.1%); liver cancer, 
n = 176 (42.9%); gastric cancer, n = 82 (20.0%)]. The mean 
duration of surgery was 4.2 h (range 1.2–12.6 h). Patients 
received an average of 13.56 g/day (range 0–15.0 g/day) 
DKT until their FBM.
A comparison of the main analysis group (n = 410) with 
all study subjects (n = 740) indicated that the proportions 
of patients differed slightly concerning the organs targeted 
for surgery. In the main analysis group, no significant dif-
ferences in background factors were found between the 
DKT and placebo groups, and the dosages were also simi-
lar between the two groups (Table 1a). The DKT treatment 
group and placebo group were comparable in the main anal-
ysis group. In the non-main analysis group (n = 330), while 
no significant differences in background factors were found 
between the DKT and placebo groups, the dosages did differ 
between the groups (Table 1b).
Our study revealed that there was a statistically significant 
difference in the primary endpoint between the DKT and 
placebo groups in the main analysis cohort [stratified log-
rank test; p = 0.004; stratified hazard ratio (HR) 1.337; 95% 
confidence interval (CI) 1.096–1.631; Fig. 1]. In contrast, 
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no significant difference in the primary outcome was noted 
between the 2 groups in the non-main analysis group (strati-
fied log-rank test; p = 0.6322; stratified HR 0.947; 95% CI 
0.756–1.185; Fig. 2). The analysis including all study sub-
jects showed that there was also no significant difference 
in the primary outcome between the two groups (strati-
fied log-rank test; p = 0.1016; stratified HR 1.131; 95% CI 
0.976–1.312).
In the main analysis group, the median time from extu-
bation to the FBM was 113.84 h (95% CI 107.0–117.03) 
in the placebo group (n = 194) and 99.09  h (95% CI 
93.75–106.17) in the DKT treatment group (n = 214), 
which was 14.75 h shorter than that in the placebo group. 
The median time from extubation to the first meal was 
Table 1  Background factors of the main analysis (a) and non-main 
analysis (b)
Factor Placebo group DKT group Total CMH test
(a) Main analysis group (group 1) n = 410 (colon: 152/liver: 176/
stomach: 82)
 Sex
  Male 128 (65.3%) 138 (64.5%) 266 (64.9%) p = 0.9933
  Female 68 (34.7%) 76 (35.5%) 144 (35.1%)
 Age
  Mean 68.0 67.8 67.9 p = 0.8733
  Range 28–88 28–88 28–88
 BMI (kg/m2)
  Mean 22.667 22.844 22.759 p = 0.8646
  Range 15.04–39.06 14.61–42.10 14.61–42.10
 Coexisting diseases
  No 100 (51.0%) 115 (53.7%) 215 (52.4%) p = 0.5060
  Yes 96 (49.0%) 99 (46.3%) 195 (47.6%)
 Medical history
  No 99 (50.5%) 118 (55.1%) 217 (52.9%) p = 0.4336
  Yes 97 (49.5%) 96 (44.9%) 193 (47.1%)
 Surgery-related complications
  No 169 (86.2%) 179 (83.6%) 348 (84.9%) p = 0.1837
  Yes 27 (13.8%) 35 (16.4%) 62 (15.1%)
 ECOG performance status
  0 184 (93.9%) 197 (92.1%) 381 (92.9%) p = 0.5566
  1 12 (6.1%) 17 (7.9%) 29 (7.1%)
 Duration of surgery(min)
  Mean 253.6 244.9 249.1 p = 0.7238
  Range 72–589 79–753 72–753
 Loss of blood volume at surgery(mL)
  Mean 458.9 513.6 487.5 p = 0.3163
  Range 0–6180 0–6800 0–6800
 Average daily dose from 2 to 8d
  Mean 13.95 13.56 13.75 p = 0.2714
  Range 0.0–15.7 0.0–15.0 0.0–15.7
 Average daily dose until defecation
  Mean 13.48 13.62 13.56 p = 0.4992
  Range 0.0–15.0 0.0–15.0 0.0–15.0
(b) Non-main analysis group n = 330 (colon: 184/liver: 33/stomach: 
113)
 Sex
  Male 121 (72.9%) 113 (68.9%) 234 (70.9%) p = 0.3712
  Female 45 (27.1%) 51 (31.1%) 96 (29.1%)
 Age
  Mean 68.0 65.9 66.9 p = 0.2276
  Range 35–91 37–88 35–91
 BMI (kg/m2)
  Mean 22.587 23.004 22.794 p = 0.4759
  Range 15.57–31.12 15.20–37.22 15.20–37.22
 Coexisting diseases
  No 89 (53.6%) 100 (61.0%) 189 (57.3%) p = 0.1479
  Yes 77 (46.4%) 64 (39.0%) 141 (42.7%)
Values represent the number of patients (proportion in each group), 
mean, range, and p values of the CMH tests. The CMH tests were 
performed using table scores for discrete variables and rank scores 
for continuous variables. The presence of a surgery-related complica-
tion (“Yes”) was defined in cases of the development of at least one 
of following diseases: ileus, anastomotic leakage, intra-abdominal 
abscess, gastrointestinal motility disorder, abdominal distention, post-
operative pancreatitis/pancreatic leak, or  bacterial peritonitis. The 
common denominator in three different randomized controlled trials 
was the postoperative administration of DKT or placebo on days 2-8 
(JFMC39-0902, 40-1001 and 42-1002)
CMH Cochran–Mantel–Haenszel test, BMI body mass index, DKT 
daikenchuto, ECOG Eastern Cooperative Oncology Group, CI confi-
dence interval, d day, JFMC the Japanese Foundation for Multidisci-
plinary Treatment of Cancer
Table 1  (continued)
Factor Placebo group DKT group Total CMH test
 Medical history
  No 100 (60.2%) 91 (55.5%) 191 (57.9%) p = 0.4330
  Yes 66 (39.8%) 73 (44.5%) 139 (42.1%)
 Surgery-related complications
  No 117 (70.5%) 128 (78.0%) 245 (74.2%) p = 0.1004
  Yes 49 (29.5%) 36 (22.0%) 85 (25.8%)
 ECOG performance status
  0 155 (93.4%) 154 (93.9%) 309 (93.6%) p = 0.8470
  1 11 (6.6%) 10 (6.1%) 21 (6.4%)
 Duration of surgery(min)
  Mean 223.0 227.0 225.0 p = 0.8393
  Range 102–522 80–585 80–585
 Loss of blood volume at surgery(mL)
  Mean 308.8 330.3 319.5 p = 0.6205
  Range 10–1400 10–3343 10–3343
 Average daily dose from 2 to 8d
  Mean 11.68 12.63 12.15 p = 0.0388
  Range 0.0–15.0 0.0–15.0 0.0–15.0
 Average daily dose until defecation
  Mean – – – –
  Range – – –
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66.5 h (interquartile range 43.0–90.9) in the placebo group 
and 63.5 h (interquartile range 40.2–89.8) in the DKT 
treatment group. The analysis including the non-main 
analysis subjects found that the median time from extuba-
tion to the FBM was 66.40 h (95% CI 60.67–71.15) in the 
placebo group (n = 158) and 65.81 h (95% CI 57.15–72.00) 
in the DKT treatment group (n = 161), both of which were 
significantly shorter than the respective values in the main 
analysis group.
Sensitivity analyses were performed using the fol-
lowing six subpopulations: age < 75 years old (n = 295), 
BMI < 30 kg/m2 (n = 393), no medical history (n = 217), no 
complications at the time of enrollment (n = 215), no sur-
gery-related complications (n = 348), and an average daily 
DKT dose of ≥ 10 g until the FBM (n = 369) (Table 2). Sta-
tistically significant differences were observed in all subpop-
ulations. In addition, there were considerable increases in 
the HRs in all subpopulations, when the absence of surgery-
related complications (n = 62; 16 ileus, 29 gastrointestinal 
motility disorders, 40 abdominal distension, 4 anastomotic 
leakage, 5 intra-abdominal abscess, 3 pancreatic fistula, and 
3 pancreatitis) was excluded as a variable.
Discussion
In the present study, DKT significantly improved the pro-
longed POI after major OAS in the main analysis group. The 
number of patients in the subgroup group (n = 410) included 
152, 176, and 82 patients with colon, liver, and gastric can-
cer, respectively. Sufficient statistical power of the pooled 
analysis including 410 patients was not achieved in the indi-
vidual RCTs due to the relatively small number of patients.
The common primary endpoint of the RCTs pooled in 
this study was the time to the FBM after the completion 
of surgery [10–12]. However, RCT results did not show 
an appreciable reduction in time to initial defecation pro-
vided by DKT, as anticipated. The authors speculate that a 
Fig. 1  Cumulative defecation 
rate after surgery in the main 
analysis group. Curves represent 
the cumulative defecation rates 
of the Daikenchuto-treated 
and placebo-treated groups 
drawn using the Kaplan–Meier 
method. Censors are depicted 
using the “+” symbol on the 
curves. DKT daikenchuto
Fig. 2  Cumulative defecation 
rate after surgery in the non-
main analysis group. Curves 
represent the cumulative defeca-
tion rates of the Daikenchuto-
treated and placebo-treated 
groups drawn using the Kaplan–
Meier method. Censors are 
depicted using the “+” symbol 
on the curves. DKT daikenchuto
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potential confounder masked the effect of DKT and hence its 
effect on the POI. DKT components are known to stimulate 
intrinsic intestinal motility factors (e.g., neurotransmitters, 
among others), but they do not act like neurotransmitters by 
themselves [7, 8]. It is possible that, in the group that recov-
ered earlier from the physiological ileus state, endogenous 
intestinal motility factors were already at work, precluding 
the effect of DKT. Therefore, excluding the patients who 
recovered from physiological POI and those who did not 
require medical treatment resulted in a group of patients 
with a high possibility of morbid ileus expression; these 
patients were used as the main analysis group in this study. 
The purpose of this study was to verify the true pharmaco-
logical action of DKT.
Although the end point of POI is controversial, the occur-
rence of a BM appears to be the most reliable endpoint [1, 3]. 
Nearly half of the patients in the present study experienced 
a BM before the first diet after surgery. These patients were 
therefore deemed to have recovered from physiologic POI 
(low incidence of pathologic POI) provided recurrent POI 
did not occur. The median time from surgery to the FBM for 
these patients was 66.4 h (95% CI 60.7–71.2) in the placebo 
group and 65.8 h (95% CI 57.2–72) in the DKT group. These 
median times with 95% CIs are defined as the category of 
physiologic POI. Therefore, to evaluate the effect of DKT on 
pathologic POI more precisely, we excluded such low-risk 
patients from the main analysis population.
The main analysis population did not experience a BM 
before the first diet after surgery. A diet is given to patients 
after surgery according to the comprehensive clinical judg-
ment of doctors based on abdomenal X-ray findings, flatus, 
and bowel sounds, even if there is no BM. Early feeding 
of patients who had undergone abdominal surgery led to a 
reduction in the length of the hospital stay, improvement of 
the metabolic status, a reduced rate of septic complications, 
and a reduced morbidity rate [15]. However, the incidence 
rate of prolonged POI following major abdominal surgery 
was 10–25% [16]. Furthermore, prolonged POI increases the 
length of the hospital stay [16].
We hypothesized that patients who do not have a BM 
before their first diet after surgery would be a suitable group 
for evaluating the effect of DKT on pathologic POI after 
OAS in the present subgroup analysis. Our study of the main 
analysis group showed that the median time from surgery 
to the FBM was 114 h (95% CI 107.0–117.03) in the pla-
cebo group and 99 h (95% CI 93.75–106.17) in the DKT 
treatment group. Both the median time and 95% CI fall out-
side the physiologic POI category and are likely to fall into 
the category of prolonged POI. These results support our 
hypothesis that the main analysis population is at risk of 
prolonged POI and requires medical treatment to recover.
The three RCTs included in the present study enrolled 
patients with three different cancers who underwent OAS 
that targeted different organs. These three different types of 
OAS are typical stressors and causes of pathological POI, 
in general. Therefore, the results from one RCT cannot be 
generalized to patients undergoing OAS for other organs. 
However, the data in the current study included patients with 
cancers of three type of OAS; therefore, our findings are 
more generalizable than those from a study on a single type 
of OAS. Although the differences in the organs were statis-
tically weighted in the present study, a larger, high-quality 
RCT evaluating the efficacy of DKT should be conducted 
in the same organ, and the surgical procedures should also 
be improved.
Several important neurally mediated mechanisms have 
been suggested as mediating the increased effective intes-
tinal motility of DKT. One proposed mechanism posits 
that DKT accelerates the acetylcholine release from cho-
linergic myenteric neurons mediated by the activation of 
5-HT receptors (5-HT3 and 5-HT4) [17, 18], and smooth 
muscles then contract due to the released acetylcholine 
Table 2  The results of the sensitivity analysis in the main analysis
Values represent the number of patients, p values of stratified log-rank tests, and stratified hazard ratios in the Daikenchuto-treated versus pla-
cebo-treated groups, along with 95% confidence intervals for the whole subgroup population and all subpopulations used in the sensitivity analy-
sis
BMI body mass index, CI confidence interval
Factor Number of patients Stratified log-rank test Stratified hazard ratio (95% CI)
Whole main analysis population n = 410 p = 0.0040 1.337 (1.096–1.631)
Subset
 Age < 75 years n = 295 p = 0.0044 1.406 (1.111–1.779)
 BMI < 30 kg/m2 n = 393 p = 0.0029 1.359 (1.110–1.665)
 No medical history n = 217 p = 0.0025 1.569 (1.169–2.104)
 No coexisting diseases n = 215 p = 0.0229 1.376 (1.044–1.814)
 No surgery-related complications n = 348 p = 0.0101 1.327 (1.069–1.647)
 Average daily dose until defecation ≥ 10 g n = 369 p = 0.0019 1.395 (1.130–1.723)
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through the stimulation of muscarinic receptors (M2R 
and M3R). Alternatively, it has been reported that DKT 
increases the plasma levels of motilin, a gastrointestinal 
polypeptide hormone, which improves morphine-induced 
constipation in humans and canines [19, 20]. As another 
potential mechanism, DKT may induce the release of sub-
stance P from primary sensory nerves through the tran-
sient receptor potential vanilloid 1 on intramucosal termi-
nal sensory nerves, which contracts smooth muscle [21, 
22]. DKT may also induce the release of serotonin through 
the transient receptor potential ankyrin 1 on enterochro-
maffin cells, resulting in coordinated peristaltic motility in 
the small intestine [23]. As a final potential mechanism, 
DKT ingredients may accelerate colonic motility by inhib-
iting the two-pore-domain potassium channel subfamily 
K (KCNK3 and KCNK9) in intestinal smooth muscle and 
neuronal cells [24]. These lines of evidence indicate that 
while DKT ingredients themselves are not neuronal trans-
mitters or neuropeptides, DKT can stimulate the release 
of neuronal transmitters and gastrointestinal hormones for 
BMs [7], mainly via the modulation of the peripheral neu-
ral machinery in the intestinal wall.
We selected subpopulations for the sensitivity analy-
sis based on the absence of postoperative complications, 
medical history, and coexisting disease, all of which are 
considered to be associated with recovery from POI. In 
addition, we used the age and BMI as additional variables 
for the subpopulations. Previous pharmacokinetic studies 
on DKT showed that the age and BMI were significantly 
and inversely correlated with the absorption of active DKT 
ingredients [14]. We also used the dosage as a variable for 
the sensitivity analysis, which showed that the absorption 
rate of active DKT ingredients was dose-dependent. The 
HRs tended to rise in subpopulations of patients who were 
< 75 years of age, who had a BMI < 30 kg/m2, and who were 
receiving more than two-thirds of the expected DKT dose.
Population pharmacokinetic models for DKT using data 
from two RCTs on DKT pharmacokinetics were developed 
in Japan and the United States [14]. Participants received 
single oral doses of 2.5, 5, or 10 g DKT. Active DKT ingre-
dients were effective for BMs in a dose-dependent manner 
and inversely correlated with the BMI and age, and ethnic 
differences between the Japanese and US participants were 
minimal. An analysis of the BMI revealed that a nearly two-
fold increase in the BMI from 18 to 30 kg/m2 was associ-
ated with a twofold decrease in the plasma concentrations 
of active DKT ingredients. We also found that the age was 
a covariate, with a threefold increase in age from 20 to 
60 years being associated with a 1.5-fold decrease in plasma 
concentrations of active DKT ingredients.
In the current study, the ranges of the BMI and age in the 
main analysis subgroup were 14.6–42.1 kg/m2 and 28–88 
years, respectively. Therefore, an evaluation of the outcomes 
adjusted by the concentrations of active ingredients of DKT 
should be conducted with consideration of the patient BMI 
and age in future RCTs.
Traditional Japanese medicines, such as DKT, were 
developed from 500 to over 1500 years ago [8, 25]. Given 
that the average life expectancy was shorter and the average 
weight lower at that time than at present, the differences in 
the blood concentrations of active DKT ingredients with 
different doses were not likely to be significant. The use 
of DKT is mentioned in a famous classical book of tradi-
tional Japanese medicine (Jin Gui Yao Lue) [26]. In that 
book, DKT is said to be more effective in slim people than 
in heavier-set people. This statement matches well with 
the results of the present study concerning patients with a 
BMI < 30 kg/m2.
Limitations
Several limitations associated with the present study warrant 
mention. First, the subgroup analysis might be confounded 
by differences in surgical procedures owing to differences 
in the cancer types and target organs among the three RCTs. 
Second, the occurrence of pathologic POI was related to 
multiple factors, including the surgical procedure, experi-
ence of the surgeon, tissue quality, hospital environment, 
total parenteral nutrition, and additional medical thera-
pies. As a result, the database was somewhat imprecise. To 
address this type of heterogeneity, larger, high-quality RCTs 
that evaluate the efficacy of DKT should be conducted, and 
more detailed analyses, such as analyses of financial con-
straints of DKT, must be performed to strengthen the reli-
ability of any conclusions.
Conclusion
This subgroup analysis of three RCTs revealed that DKT sig-
nificantly accelerated the POI recovery in patients at risk of 
pathologic POI occurrence after major OAS compared with 
the placebo group. Our findings suggest that the benefits of 
DKT might be enhanced in patients who are younger than 
75 years of age, those with a BMI < 30 kg/m2, and those 
receiving a daily DKT dosage of ≥ 10 g.
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